FDA “Approvable” Actions Increasing Under PDUFA, Agency Acknowledges

FDA is issuing "approvable" letters more frequently due to resource constraints on end-of-review negotiations, the agency acknowledges in a Federal Register notice scheduled for publication Nov. 19